US2022023303A1PendingUtilityA1
Use of riboflavin to benefit bowel health
Est. expiryDec 11, 2038(~12.4 yrs left)· nominal 20-yr term from priority
A61P 1/12A23V 2002/00A23L 33/15A61P 1/10A23V 2200/32A61K 31/525A23L 33/21A23L 33/40
38
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Riboflavin can have a beneficial effect in supporting bowel health in healthy people. Specifically it can relieve diarrhea or constipation, regulate bowel movement frequency, and regulating bowel movement urgency. The dosage brings the daily intake of riboflavin (consumed by diet and by supplement) above the RDA.
Claims
exact text as granted — not AI-modified1 . Riboflavin for the non-therapeutic use of promoting a bowel health parameter in a healthy person selected from the group consisting of:
A) normalizing diarrhea or constipation; B) regulating bowel movement frequency; and C) regulating bowel movement urgency.
2 . Riboflavin according to claim 1 wherein the total amount of riboflavin consumed by diet and by supplement is above the recommended daily amount (RDA) for the healthy person.
3 . Riboflavin according to claim 1 where the amount of riboflavin consumed in a supplement is at least 1 to 5 mg, preferably 1 to 3 mgs, and more preferably, at least 1.5 to 2 mg.
4 . Riboflavin according to claim 1 , in combination with dietary fibre.
5 . A method of promoting bowel health in a healthy person comprising: administering an effective amount of riboflavin to a person experiencing, or at risk of experiencing, at least one condition selected from the group consisting of: diarrhea, constipation, irregular bowel movement frequency, and irregular bowel movement urgency.
6 . The method according to claim 5 , wherein a total amount of riboflavin consumed by diet and by supplement is above the recommended daily amount for the healthy person.
7 . The method according to claim 6 wherein the amount of riboflavin consumed by supplement is at least 1 to 5 mg, preferably 1. to 3 mgs, and more preferably, at least 1.5 to 2 mg.
8 . The method according to claim 5 , further comprising administering dietary fibre.Join the waitlist — get patent alerts
Track US2022023303A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.